Advertisement
Advertisement
U.S. Markets close in 2 hrs 21 mins
Advertisement
Advertisement
Advertisement
Advertisement

BeiGene, Ltd. (BGNE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
135.00-1.28 (-0.94%)
As of 01:38PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close136.28
Open134.27
Bid135.12 x 1200
Ask135.68 x 900
Day's Range133.31 - 137.78
52 Week Range118.18 - 392.30
Volume114,178
Avg. Volume228,157
Market Cap14.342B
Beta (5Y Monthly)0.72
PE Ratio (TTM)N/A
EPS (TTM)-19.13
Earnings DateAug 07, 2018 - Aug 13, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est315.21
  • Bloomberg

    Latest Push by Chinese Firms to Avoid Delistings Falls Short

    (Bloomberg) -- Chinese companies are flailing in a fresh bid to avoid being booted off US stock exchanges for shirking Washington’s oversight demands. Most Read from BloombergMacKenzie Scott Files for Divorce From Science Teacher HusbandMeta to Cut Headcount for First Time, Slash Budgets Across TeamsStocks Plummet to 22-Month Low as Fed Hawks Circle: Markets WrapTrump Refuses to Delay Florida Deposition in Phone-Fraud Case Despite HurricaneTop Apple Executive Is Leaving After Making Crude Remark

  • Benzinga

    UK's NICE Recommends BeiGene's Cancer Drug For Rare Form Of Blood Cancer

    England's National Institute for Health and Care Excellence (NICE) has recommended BeiGene Ltd's (NASDAQ: BGNE) Brukinsa (zanubrutinib) for Waldenström's Macroglobulinemia (WM) in adults who have had at least one treatment, only if bendamustine plus rituximab is also suitable. This decision from NICE marks Brukinsa as the first and only treatment for WM to be recommended for routine use in England and Wales. Also Read: BeiGene's Brukinsa Tops JNJ's Imbruvica In Overall Response Rate In Leukemia

  • Business Wire

    NICE Recommends BeiGene’s BRUKINSA® (zanubrutinib) for Patients with Waldenström’s Macroglobulinemia who have had at Least One Treatment

    CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, September 19, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company that is developing and commercializing oncology medicines, today announced that England’s health technology assessment institute, the National Institute for Health and Care Excellence (NICE), has issued a final appraisal document (FAD) recommending BRUKINSA (zanubrutinib) for the treatment of Waldenström’s Macroglobulinemia (WM) in adults who have

Advertisement
Advertisement